Padecimientos y Estudios

La distribución del Sistema Endocannabinoide en el organismo humano, está conforma por receptores y moléculas llamadas endocannabinoides. Razón por la cual el cannabis puede ser utilizado como medicamento y tratar una amplia gama de padecimientos que atacan los siguientes sistemas y aparatos del cuerpo:

  • Inmunológico
  • Nervioso
  • Cardiovascular
  • Gastrointestinal
  • Respiratorio
  • Reproductor, e incluso el óseo.
 

A continuación encontrarás un compilado de artículos de relevancia médica al respecto del uso de cannabinoides en diversas enfermedades en las que la ciencia ha sugerido su efectividad. Cabe mencionar que la gran mayoría de los artículos aquí referidos son de protocolos de estudios preclínicos, de investigación en animales y con cultivos celulares desarrollados en laboratorios.

Lo anterior, debido a las legislaciones prohibicionistas de algunos países, ya que al ser muy pocos los gobiernos que permiten realizar estudios en humanos, los que existen sólo se han hecho con productos farmacéuticos derivados de la planta del Cannabis. 

Si bien es cierto que se encuentran estudios y artículos relacionados con los padecimientos y el uso de cannabis en México, todos de ellos son en fase pre clínica. Aunque en un futuro, es probable que México realice investigaciones clínicas para contribuir al desarrollo científico del cannabis medicinal. 

In vivo evidence for therapeutic of canabidio cbd for alzheimer disease

Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer’s Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.

Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARγ involvement.

Cannabinoids in late-onset Alzheimer’s disease.

Activation of CB2 receptor system restores cognitive capacity and hippocampal Sox2 expression in a transgenic mouse model of Alzheimer’s disease.

CB₂ receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer’s disease.

CB2 receptor and amyloid pathology in frontal cortex of Alzheimer’s disease patients.

Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer’s Disease Agents.

Endocannabinoid regulation of amyloid-induced neuroinflammation.

Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer’s Disease.

Elevation of Plasma 2-Arachidonoylglycerol Levels in Alzheimer’s Disease Patients as a Potential Protective Mechanism against Neurodegenerative Decline.

Normal aging in rats and pathological aging in human Alzheimer’s disease decrease FAAH activity: modulation by cannabinoid agonists.

Cannabinoid receptor 2 deficiency results in reduced neuroinflammation in an Alzheimer’s diseasemouse model.

The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer’s disease.

Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic.

Endocannabinoid signalling in Alzheimer’s disease.

In vivo type 1 cannabinoid receptor availability in Alzheimer’s disease.

Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer’s disease.

The therapeutic potential of the endocannabinoid system for Alzheimer’s disease.

Endocannabinoids prevent β-amyloid-mediated lysosomal destabilization in cultured neurons.

The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages.

Endocannabinoids in Alzheimer’s disease and their impact on normative cognitive performance: a case-control and cohort study.

The endocannabinoid system and Alzheimer’s disease.

The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models.

Endocannabinod Signal Dysregulation in Autism Spectrum Disorders: A Correlation Link between Inflammatory State and Neuro-Immune Alterations.

Endocannabinoid Signaling in Autism

Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid.

Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders.

Mutations found in individuals with autism interfere with endocannabinoid signaling in the brain

Enhancement of Anandamide-Mediated Endocannabinoid Signaling Corrects Autism-Related Social Impairment.

Deficient adolescent social behavior following early-life inflammation is ameliorated by augmentation of anandamide signaling.

Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders.

A Novel Approach to the Symptomatic Treatment of Autism and anxiety and reduce compulsive ordering, collect

Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life.

The Endocannabinoid System and Anxiety.

Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects

Evidences for the Anti-panic Actions of Cannabidiol.

Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa.

Cannabidiol as a Potential Treatment for Anxiety Disorders.

Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test.

Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.

The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system.

Cannabidiol Regulation of Learned Fear: Implications for Treating Anxiety-Related Disorders.

Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report.

Cannabidiol Oil for Decreasing Addictive Use of Marijuana: A Case Report.

Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.

General

Publicaciones del Grupo de Señalización por Cannabinoides dirigido por el Dr. Manuel Guzmán

Towards the use of cannabinoids as antitumour agents.

A selective review of medical cannabis in cancer pain management.

Cannabis Use in Palliative Oncology: A Review of the Evidence for Popular Indications.

Cannabinoids – a new weapon against cancer?

Cannabidiol as potential anticancer drug.

A user’s guide to cannabinoid therapies in oncology.

Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics.

Integrating cannabis into clinical cancer care.

Cannabidiol, a novel inverse agonist for GPR12.

Cannabidiol inhibits angiogenesis by multiple mechanisms.

Cannabis and cancer: toward a new understanding.

Systematic Review of the Use of Phytochemicals for Management of Pain in Cancer Therapy.

The influence of biomechanical properties and cannabinoids on tumor invasion.

Antitumorigenic targets of cannabinoids – current status and implications.

Cerebro

Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect.

Quantitative Analyses of Synergistic Responses between Cannabidiol and DNA-Damaging Agents on the Proliferation and Viability of Glioblastoma and Neural Progenitor Cells in Culture.

A combined preclinical therapy of cannabinoids and temozolomide against glioma.

Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner.

Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme.

Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression.

Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.

In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma.

Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells.

Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients’ cells.

Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.

Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines.

Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism.

De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis.

Pulmón

Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors.

Anti-proliferative and anti-angiogenic effects of CB2R agonist (JWH-133) in non-small lung cancer cells (A549) and human umbilical vein endothelial cells: an in vitro investigation.

Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1.

COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells.

Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells.

Estomago

WIN 55,212-2 Inhibits the Epithelial Mesenchymal Transition of Gastric Cancer Cells via COX-2 Signals.

Colon

Inhibition of Wnt/β-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer.

Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent.

CB2 cannabinoid receptor activation promotes colon cancer progression via AKT/GSK3β signaling pathway.

GPR55 promotes migration and adhesion of colon cancer cells indicating a role in metastasis.

Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival.

O-1602, an atypical cannabinoid, inhibits tumor growth in colitis-associated colon cancer through multiple mechanisms.

Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer.

Próstata

Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.

Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent.

Seno

Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration.

Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy.

Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation.

Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer.

Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.

Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer.

Páncreas

Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes.

Urológico

Systematic review of the potential role of cannabinoids as antiproliferative agents for urological cancers.

Targeting the endogenous cannabinoid system to treat neuropathic pain.

The endocannabinoid system as a potential therapeutic target for pain modulation.

Therapeutic potential of inhibitors of endocannabinoid degradation for the treatment of stress-related hyperalgesia in an animal model of chronic pain. 

Expression of matrix metalloproteinases and components of the endocannabinoid system in the knee joint are associated with biphasic pain progression in a rat model of osteoarthritis.

Early blockade of joint inflammation with a fatty acid amide hydrolase inhibitor decreases end-stage osteoarthritis pain and peripheral neuropathy in mice.

Compensatory Activation of Cannabinoid CB2 Receptor Inhibition of GABA Release in the Rostral Ventromedial Medulla in Inflammatory Pain.

Dual-Acting Compounds Targeting Endocannabinoid and Endovanilloid Systems-A Novel Treatment Option for Chronic Pain Management.

Endocannabinoid system: Role in depression, reward and pain control (Review).

Rescue of Impaired mGluR5-Driven Endocannabinoid Signaling Restores Prefrontal Cortical Output to Inhibit Pain in Arthritic Rats.

Cannabinoids in the management of chronic pain: a front line clinical perspective.

A Double Whammy: Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To Treat Pain and Inflammation.

Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.

A selective review of medical cannabis in cancer pain management.

Perioperative Patient Beliefs Regarding Potential Effectiveness of Marijuana (Cannabinoids) for Treatment of Pain: A Prospective Population Survey.

Chronic pain patients’ perspectives of medical cannabis.

Cannabinoid Buccal Spray for Chronic Non-Cancer or Neuropathic Pain: A Review of Clinical Effectiveness, Safety, and Guidelines [Internet].

Opioids Out, Cannabis In Negotiating the Unknowns in Patient Care for Chronic Pain

Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain.

Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data.

Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence.

The role of the endocannabinoid system in pain.

Experience of adjunctive cannabis use for chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study.

Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations.

Dronabinol and chronic pain: importance of mechanistic considerations.

Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain.

Prescribing marijuana for chronic pain.

The analgesic potential of cannabinoids.

Cannabinoids in chronic pain and palliative care.

Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.

Endocannabinoid system acts as a regulator of immune homeostasis in the gut.

Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis.

Irritable Bowel Syndrome: A Dysfunction of the Endocannabinoid System?

The Role of the Endocannabinoid System in the Brain-Gut Axis.

Association between single nucleotide polymorphisms of the transient receptor potential vanilloid 1 (TRPV-1) gene and patients with irritable bowel syndrome in Korean populations.

Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study.

The gastrointestinal tract – a central organ of cannabinoid signaling in health and disease.

Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract.

Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

Role of cannabis in digestive disorders.

Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides.

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

Cannabis for inflammatory bowel disease.

Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.

The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis.

Cannabis and Multiple Sclerosis—The Way Forward´

Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice.

Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients.

Cannabis and cognitive functioning in multiple sclerosis: The role of gender.

Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity

Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray.

Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis.

A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis.

Clinical perspectives on medical marijuana (cannabis) for neurologic disorders.

Advances in the management of MS spasticity: recent observational studies.

Advances in the Management of Multiple Sclerosis Spasticity: Multiple Sclerosis Spasticity Nervous Pathways

Advances in the management of multiple sclerosis spasticity: recent clinical trials.

Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters.

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.

Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis.

Cannabinoids in Parkinson’s Disease.

Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target.

Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson’s Disease.

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease.

Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection.

The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats.

Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson’s disease.

Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial.

Cannabinoid agonists stimulate [3H]GABA release in the globus pallidus of the rat when G(i) protein-receptor coupling is restricted: role of dopamine D2 receptors.

Prospects for cannabinoid therapies in basal ganglia disorders.

Cannabidiol for the treatment of psychosis in Parkinson’s disease.

WhatsApp chat
A %d blogueros les gusta esto: